These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19554535)

  • 21. Parathyroidectomy in the calcimimetic era.
    Elder GJ
    Nephrology (Carlton); 2005 Oct; 10(5):511-5. PubMed ID: 16221104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of secondary hyperparathyroidism].
    Cunningham J
    Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
    Block GA; Spiegel DM; Ehrlich J; Mehta R; Lindbergh J; Dreisbach A; Raggi P
    Kidney Int; 2005 Oct; 68(4):1815-24. PubMed ID: 16164659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial.
    Hiramatsu R; Ubara Y; Sawa N; Hoshino J; Hasegawa E; Kawada M; Imafuku A; Sumida K; Mise K; Hayami N; Suwabe T; Takaichi K
    Am J Kidney Dis; 2015 Jul; 66(1):175-7. PubMed ID: 25979349
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Secondary hyperparathyroidism].
    Imanishi Y; Inaba M
    Nihon Rinsho; 2006 Jun; Suppl 2():31-6. PubMed ID: 16817344
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series.
    Achinger SG; Mizani MR; Ayus JC
    Hemodial Int; 2010 Apr; 14(2):193-9. PubMed ID: 20337743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium thiosulfate, bisphosphonates, and cinacalcet for calciphylaxis.
    Raymond CB; Wazny LD; Sood AR
    CANNT J; 2009; 19(4):25-7; quiz 28-9. PubMed ID: 20136032
    [No Abstract]   [Full Text] [Related]  

  • 30. Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including long-term data.
    Salmhofer H; Franzen M; Hitzl W; Koller J; Kreymann B; Fend F; Hauser-Kronberger C; Heemann U; Berr F; Schmaderer C
    Kidney Blood Press Res; 2013; 37(4-5):346-59. PubMed ID: 24247072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.
    Martin CJ; Reams SM
    J Ren Nutr; 2003 Apr; 13(2):133-6. PubMed ID: 12671837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sevelamer hydrochloride on bone in experimental uremic rats.
    Kuwahara M; Inoshita S; Terada Y; Sasaki S
    Ther Apher Dial; 2009 Feb; 13(1):42-8. PubMed ID: 19379169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].
    Hamano T
    Clin Calcium; 2009 Apr; 19(4):529-36. PubMed ID: 19329832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.
    Padhi D; Harris R; Sullivan JT
    Clin Drug Investig; 2014 Aug; 34(8):537-44. PubMed ID: 24935051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Sevelamer reduce mortality by slowing of progression of coronary calcification?
    Badve SV; Magner PO
    Kidney Int; 2007 Jun; 71(12):1328-9. PubMed ID: 17554361
    [No Abstract]   [Full Text] [Related]  

  • 37. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal osteodystrophy.
    Parfitt AM
    Orthop Clin North Am; 1972 Nov; 3(3):681-98. PubMed ID: 4565585
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New agents for the treatment of renal osteodystrophy.
    Ledger S
    CANNT J; 2004; 14(4):16-21; quiz 21-2. PubMed ID: 15673151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.